Epidemiologic Registry PETHEMA LMA 2015

Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia

NCT06225128 ·Status: RECRUITING

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

NCT01041040 ·Status: COMPLETED ·Phase: PHASE4

Registry on Hypomethylating Agents in Myeloid Neoplasms

NCT01595295 ·Status: COMPLETED

Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

NCT04460950 ·Status: RECRUITING

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

NCT00464217 ·Status: COMPLETED ·Phase: PHASE4

Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital

NCT05558943 ·Status: NOT_YET_RECRUITING

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

NCT05772559 ·Status: RECRUITING

ObServatory Children Acute RElated Therapy Leukemia

NCT04450784 ·Status: UNKNOWN

Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.

NCT03311815 ·Status: COMPLETED

Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.

NCT03902769 ·Status: UNKNOWN ·Phase: NA

ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia

NCT02619071 ·Status: UNKNOWN ·Phase: NA

Assessing Refractoriness and Infectious Survival Events in AML

NCT06709235 ·Status: COMPLETED

Frequency and Risk Factors of Acute Myeloid Leukemia

NCT05787951 ·Status: UNKNOWN

Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain

NCT03435341 ·Status: COMPLETED

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

NCT03188874 ·Status: RECRUITING

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

NCT06379360 ·Status: RECRUITING ·Phase: PHASE2

Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations

NCT07254611 ·Status: COMPLETED

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia

NCT05587049 ·Status: RECRUITING

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

NCT02863458 ·Status: WITHDRAWN

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

NCT04589728 ·Status: COMPLETED

Acute Myeloid Leukemia Registry

NCT05979675 ·Status: RECRUITING

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

NCT06713837 ·Status: RECRUITING ·Phase: PHASE3

Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML

NCT02461537 ·Status: COMPLETED ·Phase: PHASE3

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

NCT05048615 ·Status: COMPLETED ·Phase: PHASE2

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project

NCT01252485 ·Status: RECRUITING